Influence of L prolyl L leucyl glycine amide on growth hormone secretion in normal and acromegalic subjects

G. Faglia, A. Paracchi, C. Ferrari, P. Beck-Peccoz, B. Ambrosi, P. Travaglini, A. Spada, C. Oliver

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Melanocyte Release Inhibiting Peptide (MRIP I) did not affect circulating levels of ACTH, LH, FSH, TSH, PRL, β MSH and insulin when iv infused (5.0 mg in 5 min plus 0.4 mg/min for 70-115 min), while it significantly reduced serum GH response to hypoglycemia in normal subjects and lowered serum GH levels in acromegalics. There was no correlation between the fall in serum GH after MRIP and after dopaminergic drugs in acromegaly. These data are compatible with either a direct suppressive action exerted by MRIP I at pituitary level or an extra pituitary effect not involving dopaminergic pathways. It can be speculated that since labelled MRIP I accumulates in the pineal and melatonin blunts GH response to hypoglycemia, the pineal gland might be involved in the MRIP I induced suppression of GH secretion.

Original languageEnglish
Pages (from-to)991-994
Number of pages4
JournalJournal of Clinical Endocrinology and Metabolism
Volume42
Issue number5
Publication statusPublished - 1976

Fingerprint

prolyl-leucyl-glycine
Melanocytes
Growth Hormone
Peptides
Hypoglycemia
Serum
Melanocyte-Stimulating Hormones
Dopamine Agents
Acromegaly
Pineal Gland
Melatonin
Adrenocorticotropic Hormone
Insulin
glycine amide

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Faglia, G., Paracchi, A., Ferrari, C., Beck-Peccoz, P., Ambrosi, B., Travaglini, P., ... Oliver, C. (1976). Influence of L prolyl L leucyl glycine amide on growth hormone secretion in normal and acromegalic subjects. Journal of Clinical Endocrinology and Metabolism, 42(5), 991-994.

Influence of L prolyl L leucyl glycine amide on growth hormone secretion in normal and acromegalic subjects. / Faglia, G.; Paracchi, A.; Ferrari, C.; Beck-Peccoz, P.; Ambrosi, B.; Travaglini, P.; Spada, A.; Oliver, C.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 42, No. 5, 1976, p. 991-994.

Research output: Contribution to journalArticle

Faglia, G, Paracchi, A, Ferrari, C, Beck-Peccoz, P, Ambrosi, B, Travaglini, P, Spada, A & Oliver, C 1976, 'Influence of L prolyl L leucyl glycine amide on growth hormone secretion in normal and acromegalic subjects', Journal of Clinical Endocrinology and Metabolism, vol. 42, no. 5, pp. 991-994.
Faglia, G. ; Paracchi, A. ; Ferrari, C. ; Beck-Peccoz, P. ; Ambrosi, B. ; Travaglini, P. ; Spada, A. ; Oliver, C. / Influence of L prolyl L leucyl glycine amide on growth hormone secretion in normal and acromegalic subjects. In: Journal of Clinical Endocrinology and Metabolism. 1976 ; Vol. 42, No. 5. pp. 991-994.
@article{c824f4c1b23c4e54828aa865c04a05a4,
title = "Influence of L prolyl L leucyl glycine amide on growth hormone secretion in normal and acromegalic subjects",
abstract = "Melanocyte Release Inhibiting Peptide (MRIP I) did not affect circulating levels of ACTH, LH, FSH, TSH, PRL, β MSH and insulin when iv infused (5.0 mg in 5 min plus 0.4 mg/min for 70-115 min), while it significantly reduced serum GH response to hypoglycemia in normal subjects and lowered serum GH levels in acromegalics. There was no correlation between the fall in serum GH after MRIP and after dopaminergic drugs in acromegaly. These data are compatible with either a direct suppressive action exerted by MRIP I at pituitary level or an extra pituitary effect not involving dopaminergic pathways. It can be speculated that since labelled MRIP I accumulates in the pineal and melatonin blunts GH response to hypoglycemia, the pineal gland might be involved in the MRIP I induced suppression of GH secretion.",
author = "G. Faglia and A. Paracchi and C. Ferrari and P. Beck-Peccoz and B. Ambrosi and P. Travaglini and A. Spada and C. Oliver",
year = "1976",
language = "English",
volume = "42",
pages = "991--994",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "5",

}

TY - JOUR

T1 - Influence of L prolyl L leucyl glycine amide on growth hormone secretion in normal and acromegalic subjects

AU - Faglia, G.

AU - Paracchi, A.

AU - Ferrari, C.

AU - Beck-Peccoz, P.

AU - Ambrosi, B.

AU - Travaglini, P.

AU - Spada, A.

AU - Oliver, C.

PY - 1976

Y1 - 1976

N2 - Melanocyte Release Inhibiting Peptide (MRIP I) did not affect circulating levels of ACTH, LH, FSH, TSH, PRL, β MSH and insulin when iv infused (5.0 mg in 5 min plus 0.4 mg/min for 70-115 min), while it significantly reduced serum GH response to hypoglycemia in normal subjects and lowered serum GH levels in acromegalics. There was no correlation between the fall in serum GH after MRIP and after dopaminergic drugs in acromegaly. These data are compatible with either a direct suppressive action exerted by MRIP I at pituitary level or an extra pituitary effect not involving dopaminergic pathways. It can be speculated that since labelled MRIP I accumulates in the pineal and melatonin blunts GH response to hypoglycemia, the pineal gland might be involved in the MRIP I induced suppression of GH secretion.

AB - Melanocyte Release Inhibiting Peptide (MRIP I) did not affect circulating levels of ACTH, LH, FSH, TSH, PRL, β MSH and insulin when iv infused (5.0 mg in 5 min plus 0.4 mg/min for 70-115 min), while it significantly reduced serum GH response to hypoglycemia in normal subjects and lowered serum GH levels in acromegalics. There was no correlation between the fall in serum GH after MRIP and after dopaminergic drugs in acromegaly. These data are compatible with either a direct suppressive action exerted by MRIP I at pituitary level or an extra pituitary effect not involving dopaminergic pathways. It can be speculated that since labelled MRIP I accumulates in the pineal and melatonin blunts GH response to hypoglycemia, the pineal gland might be involved in the MRIP I induced suppression of GH secretion.

UR - http://www.scopus.com/inward/record.url?scp=0017063945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017063945&partnerID=8YFLogxK

M3 - Article

C2 - 5465

AN - SCOPUS:0017063945

VL - 42

SP - 991

EP - 994

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 5

ER -